The low molecular weight heparin (LMWH) market revolves around a class of anticoagulant medications derived from standard heparin. LMWHs are used to prevent and treat blood clots in various medical conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and during surgical procedures. They are preferred over unfractionated heparin due to their predictable pharmacokinetics, lower risk of bleeding, and ease of administration.